Talaris Therapeutics Inc - TALS STOCK NEWS

IMPACT

SENTIMENT

10/17/2023 05:47 PM

TALS : Nasdaq

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

IMPACT

SENTIMENT

10/06/2023 05:09 PM

TALS : Nasdaq

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

IMPACT

SENTIMENT

06/22/2023 07:30 AM

TALS : Nasdaq

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

IMPACT

SENTIMENT

05/26/2023 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Announces Leadership Transition

IMPACT

SENTIMENT

02/16/2023 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

IMPACT

SENTIMENT

11/22/2022 07:00 AM

TALS : Nasdaq

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

IMPACT

SENTIMENT

11/10/2022 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

IMPACT

SENTIMENT

11/07/2022 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

IMPACT

SENTIMENT

10/20/2022 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

IMPACT

SENTIMENT

10/17/2022 07:00 AM

TALS : Nasdaq

Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

Talaris Therapeutics Inc

Nasdaq:TALS

TALS Stock Data

Industry Research and Development in Biotechnology

Sector Professional, Scientific, and Technical Services

Website Link

About TALS

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.